English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Age-related macular degeneration (AMD) was first described in 1885 by Otto Haab as a disease in patients above 50 years of age\udwith progressive retinal pigment epithelial and atrophic degenerations of the macula reducing the central visual acuity. AMD is a\udneurodegenerative disease and is now the most common cause of registrable blindness in the western world. The prevalence of the disease\udis given as 10% in 65-75-year-old population and as 25% after 75 of age. AMD is a multi-faceted and complex condition. Although\uddifferent forms of AMD share some common underlying pathological features and causes, there are unique mechanisms for each form.\udEffective therapies should be derived from in-depth knowledge about each subtype of AMD and should be tailored to address the specific\udneeds in each disease subtype. (Turk J Ophthalmol 2014; 44: 476-80

Yaşa Bağlı Makula Dejenerasyonu Sınıflandırma ve Patogenez